| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Molecular Formula |
C34H36CL2N4O4SN
|
|---|---|
| Molecular Weight |
754.29
|
| Exact Mass |
754.114
|
| CAS # |
106344-20-1
|
| Appearance |
Brown to reddish brown solid powder
|
| Boiling Point |
1096.1ºC at 760mmHg
|
| Flash Point |
616.7ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| LogP |
1.887
|
| SMILES |
[Cl-][Sn+4]123([N-]4C5C(C)=C(CC)C4=CC4C(C)=C(CC)C(=CC6=C(C)C(CCC(=O)[O-])=C(C=C7C(CCC(=O)[O-])=C(C)C(C=5)=N17)[N-]26)N3=4)[Cl-].[H+]
|
| Chemical Name |
Stannate(2-), dichloro(7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanato(4-)-N21,N22,N23,N24)-, dihydrogen, (OC-6-13)-
|
| Synonyms |
Stannsoporfin. tin (IV) mesoporphyrin IX dichlorideStannsoporfin USAN SNMPP SnMP Sn MesoporphyrinTin mesoporphyrin Stanate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.56 mg/mL (~7.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (0.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3258 mL | 6.6288 mL | 13.2575 mL | |
| 5 mM | 0.2652 mL | 1.3258 mL | 2.6515 mL | |
| 10 mM | 0.1326 mL | 0.6629 mL | 1.3258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00076960 | NO LONGER AVAILABLE | Drug: Stanate (TM) [stannsoporfin, tin-mesoporphyrin] | Hyperbilirubinemia Neonatal Jaundice |
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | ||
| NCT02685137 | COMPLETED | Drug: stannsoporfin Other: Sham Injection |
Nutritional and Metabolic Diseases | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2002-05-01 | Phase 3 |
| NCT02000830 | COMPLETED | Drug: Stannsoporfin Drug: Placebo |
Hyperbilirubinemia, Neonatal | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2013-10-17 | |
| NCT00115544 | COMPLETED | Drug: Stanate | Hyperbilirubinemia | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2005-09 | Phase 2 |
| NCT01887327 | COMPLETEDWITH RESULTS | Procedure: Phototherapy Drug: Stannsoporfin Drug: Placebo |
Hyperbilirubinemia, Neonatal Jaundice, Neonatal |
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2013-10-16 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
